Glucagon-like peptide 1 (GLP-1) agonists are a class of medications that improves blood sugar control and drives weight loss. Omada is helping customers and prospects navigate this new space by ensuring members who choose to get a prescription are taking it in conjunction with our behavior change prevention and diabetes programs, as outlined by the FDA.
Analysis shows Omada members maintained weight, with minimal (0.8%) average weight change, one year after discontinuing GLP-1s for weight loss
Read Article
Error - something went wrong!
Become an Omada Insider, subscribe to our monthly newsletter
Thank you!
Omada Insights Lab shows virtual lifestyle programs may help maintain weight post-GLP-1 discontinuation, with 63.2% of participants maintaining or losing weight after a year.
Read Resource
In this ~2-minute video, Omada's Senior Director of Clinical and Translational Research, Sarah Linke, summarizes findings of our July 2025 clinical white paper on GLP-1 Persistence
Read Article
New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada’s companion program can help sustain GLP-1 use, delivering on clinical trials' promises
Read Article
Medication persistence, or remaining on a medication as prescribed, is crucial for meaningful obesity management outcomes.
Read Resource
On May 20, 2025, Omada Horizon Day showcased how our AI-powered innovations are transforming member relationships with food. Watch the recording of our Spring 2025 product innovation unveiling!
Watch Video
Why GLP-1s are not a silver bullet for obesity, the role of behavior change support teams and how they complement obesity medicine specialists, and how providers can achieve optimal outcomes.
Read Article
This edition covers the imminent expansion of GLP-1s on a worldwide scale, the global burden and prevalence of obesity and chronic diseases, and the clinical and economic realities of GLP-1 expansion.
Read Article
Self-efficacy is key for long-term GLP-1 weight loss success. Find out how Omada’s Enhanced GLP-1 Care Track helps members achieve sustainable weight health.
Read Article
This analysis evaluated demographic & clinical characteristics of adults without diabetes who reported recent use of GLP-1s for weight loss while enrolled in a digital weight management program.
Read Article
As the GLP-1 conversation evolves, Omada Health is updating its industry FAQs to deliver timely data and insights for virtual care buyers.
Read Article
Should you trust healthcare AI? Learn about safe development and deployment practices, and the future of AI regulation in healthcare.
Read Article
Become an Omada Insider, subscribe to our monthly newsletter.
Sign me upOmada Health presented three posters at the Society of Behavioral Medicine's Annual Meeting. New data demonstrates behavioral, mental, and physical health benefits of Omada's cardiometabolic programs.
Read Article
This analysis found that providing Omada members the opportunity to make a guided decision about curriculum theme resulted in greater engagement compared to receiving content in a standardized order.
Read Article
In a survey of over 2,000 doctors, a majority believed GLP-1s need to be paired with changes in diet and exercise to be effective in driving healthy weight loss.
Read Article
What do doctors think of GLP-1s? New survey reveals prescription trends, patient safety concerns, and how telehealth prescribers affect care amidst rising demand for weight loss medications.
Read Resource
Meaningful engagement improves patient outcomes in virtual care programs, including GLP-1 programs. Find out which types of engagement are effective.
Read Article
Real-world data analysis shows Omada members, on average, experienced virtually no weight gain 16 weeks after discontinuing a GLP-1 compared to an average of 6-7% weight gain estimated from trial data
Read Article
Is keeping weight off after GLP-1s a concern for your members? Omada’s 16-week analysis reveals how tailored tools and support can help lead to successful weight maintenance.
Read Resource
Discover early outcomes and insights on health behavior and weight loss with Omada's Enhanced GLP-1 Care Track, specifically designed for individuals on GLP-1s seeking supportive programs.
Read Resource
Loading More...
